Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus: A protocol for systematic review and network meta-analysis

BACKGROUND: Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus. It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Dong, Youzi, Li, Baohua, Ning, Bobiao, Zhao, Quanlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276269/
https://www.ncbi.nlm.nih.gov/pubmed/35512071
http://dx.doi.org/10.1097/MD.0000000000029154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276269/
https://www.ncbi.nlm.nih.gov/pubmed/35512071
http://dx.doi.org/10.1097/MD.0000000000029154

Ejemplares similares